NovoSeven®

Manufacturer: NovoNordisk Pharmaceuticals
Generic Name: Coagulation Factor VIIa (Recombinant), rFVIIa

Indications: NovoSeven is indicated for:

• treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with acquired hemophilia

• prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhinitors to Factor VIII or Factor IX and in patients with acquired hemophilia

• treatment of bleeding episodes in patients with congenital FVII deficiency

• prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency

NovoSeven should be administered to patients only under the supervision of a physician experienced in the treatment of bleeding disorders.

NovoSeven® Product Insert

How Supplied: 1.2mg vial, 2.4mg vial, 4.8mg vial

http://www.novonordisk.com